Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Patrick Tamukong"'
Autor:
Minhyung Kim, Patrick Tamukong, Gloria Cecilia Galvan, Qian Yang, Amanda De Hoedt, Michael R. Freeman, Sungyong You, Stephen Freedland
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-16 (2024)
Abstract Background Black men are at a higher risk of prostate cancer (PC) diagnosis and present with more high-grade PC than White men in an equal access setting. This study aimed to identify differential transcriptional regulation between Black and
Externí odkaz:
https://doaj.org/article/d38505374cca43d2861e14d8e5fe8a11
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 163, Iss , Pp 114871- (2023)
CD4 + regulatory T cells (Tregs) play a central role in regulating and suppressing anti-tumor immune responses. FoxP3 is a transcription factor and master regulator of the Treg lineage. We developed and characterized a proteolysis targeting chimeric
Externí odkaz:
https://doaj.org/article/4439479d37504046884f0cc22a7356b6
Autor:
Shengchen Su, Sungyong You, Yanping Wang, Patrick Tamukong, Michael J. Quist, Catherine S. Grasso, Hyung L. Kim
Publikováno v:
Cancer letters. 555
Antitumor immunity requires lymphocytes to localize to the tumor. Prostate cancers (PCs) are immunologically cold and tend to lack T-cell infiltration. Most advanced PCs are insensitive to PD1 blockade therapies. Using syngeneic RM1 prostate tumors,
Autor:
Shengchen Su, Sungyong You, Yanping Wang, Patrick Tamukong, Catherine S. Grasso, Hyung L. Kim
Publikováno v:
Cancer Research. 82:4178-4178
Prostate cancers have low immune infiltration and do not respond to PD1 blockade immunotherapy. The objective of this study was to examine the effect of PAK4 inhibition on anti-tumor immune response in preclinical prostate cancer models. C57BL/6J mic
Autor:
Patrick Tamukong, Paige Kuhlmann, Sungyong You, Shengchen Su, Yanping Wang, Eric Jay Small, Brian I. Rini, Susan Halabi, Jessica Janes, Stephen J. Freedland, Hyung Lae Kim
Publikováno v:
Journal of Clinical Oncology. 40:370-370
370 Background: Clear cell renal cell carcinoma (ccRCC) is characterized by defects in the Von Hippel-Lindau/hypoxia-inducible factor (VHL/HIF) pathway. Several FDA-approved RCC therapies target the products of HIF-response genes. HIF2A is a promisin